Connecta Therapeutics
Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome.
€3.1MClinical development financing
ParticipantPI
Prous Institute for Biomedical Research
Activity from announced rounds
All recorded activity
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $3.6M 1 disclosed · full round size, not this investor’s share